Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MLYCD | O95822 | 1/20 | 0.64 |
| ▸ | BRD4 | O60885 | 16/20 | 0.61 |
| ▸ | BRD2 | P25440 | 5/20 | 0.61 |
| ▸ | BRD3 | Q15059 | 4/20 | 0.49 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.45 |
| ▸ | ERN1 | O75460 | 1/20 | 0.45 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.44 |
| ▸ | PGR | P06401 | 1/20 | 0.44 |
| ▸ | JAK2 | O60674 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8300240 | 0.80 | BRD4 (0.70) | MLYCDBRD4BRD2BRD3CREBBP | |
| SCHEMBL10145031 | 0.80 | BRD4 (0.59) | MLYCDBRD4BRD2BRD3CREBBP | |
| SCHEMBL19754237 | 0.79 | BRD4 (0.47) | MLYCDBRD4BRD2BRD3 | |
| SCHEMBL4427643 | 0.78 | MLYCD (1.00) | MLYCDBRD4BRD2 | |
| SCHEMBL3885694 | 0.77 | BRD4 (0.66) | MLYCDBRD4BRD2BRD3CREBBP | |
| SCHEMBL1772573 | 0.77 | BRD4 (0.66) | MLYCDBRD4BRD2BRD3CREBBP | |
| SCHEMBL16404607 | 0.77 | BRD4 (0.66) | MLYCDBRD4BRD2 | |
| SCHEMBL14678367 | 0.77 | BRD4 (0.66) | MLYCDBRD4BRD2BRD3CREBBP | |
| SCHEMBL12362813 | 0.77 | BRD4 (0.66) | MLYCDBRD4BRD2CREBBPERN1 | |
| 3,5-Dimethyl-4-Phenylisoxazole SCHEMBL12134072 | 0.76 | BRD4 (1.00) | MLYCDBRD4BRD2CREBBP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090291945-A1 | CYSTEINE PROTEASE INHIBITORS | TEIJIN PHARMA LIMITED (JP) | 2009-11-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090291945-A1 | CYSTEINE PROTEASE INHIBITORS | CTSE, SPINT2, CTSF | MLYCD 4298/4885BRD4 1977/4885BRD2 3288/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.